🚀 VC round data is live in beta, check it out!
StemRIM Valuation Multiples
Discover revenue and EBITDA valuation multiples for StemRIM and similar public comparables like Cardiff Oncology, Maat Pharma, Medivir, Genelux and more.
StemRIM Overview
About StemRIM
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.
Founded
2006
HQ
Employees
36
Website
Sectors
Financials (LTM)
EV
$70M
StemRIM Financials
StemRIM reported last 12-month revenue of — and negative EBITDA of ($13M).
In the same LTM period, StemRIM generated — in gross profit, ($13M) in EBITDA losses, and had net loss of ($13M).
Revenue (LTM)
StemRIM P&L
In the most recent fiscal year, StemRIM reported revenue of — and EBITDA of ($12M).
StemRIM expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($13M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($12M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
StemRIM Stock Performance
StemRIM has current market cap of $122M, and enterprise value of $70M.
Market Cap Evolution
StemRIM's stock price is $1.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70M | $122M | -2.7% | XXX | XXX | XXX | $-0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStemRIM Valuation Multiples
StemRIM trades at (5.3x) EV/EBITDA.
EV / Revenue (LTM)
StemRIM Financial Valuation Multiples
As of April 18, 2026, StemRIM has market cap of $122M and EV of $70M.
Equity research analysts estimate StemRIM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
StemRIM has a P/E ratio of (9.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV/EBITDA | (5.3x) | XXX | (5.9x) | XXX | XXX | XXX |
| EV/EBIT | (5.2x) | XXX | (5.6x) | XXX | XXX | XXX |
| P/E | (9.3x) | XXX | (10.1x) | XXX | XXX | XXX |
| EV/FCF | (7.0x) | XXX | (7.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified StemRIM Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
StemRIM Margins & Growth Rates
StemRIM's revenue in the last fiscal year declined by (100%).
StemRIM's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
StemRIM Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (3%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
StemRIM Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| StemRIM | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiff Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Maat Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
StemRIM M&A Activity
StemRIM acquired XXX companies to date.
Last acquisition by StemRIM was on XXXXXXXX, XXXXX. StemRIM acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by StemRIM
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStemRIM Investment Activity
StemRIM invested in XXX companies to date.
StemRIM made its latest investment on XXXXXXXX, XXXXX. StemRIM invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by StemRIM
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout StemRIM
| When was StemRIM founded? | StemRIM was founded in 2006. |
| Where is StemRIM headquartered? | StemRIM is headquartered in Japan. |
| How many employees does StemRIM have? | As of today, StemRIM has over 36 employees. |
| Is StemRIM publicly listed? | Yes, StemRIM is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of StemRIM? | StemRIM trades under 4599 ticker. |
| When did StemRIM go public? | StemRIM went public in 2019. |
| Who are competitors of StemRIM? | StemRIM main competitors are Cardiff Oncology, Maat Pharma, Medivir, Genelux. |
| What is the current market cap of StemRIM? | StemRIM's current market cap is $122M. |
| Is StemRIM profitable? | No, StemRIM is not profitable. |
| What is the current EBITDA of StemRIM? | StemRIM has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of StemRIM? | Current EBITDA multiple of StemRIM is (5.3x). |
| What is the current FCF of StemRIM? | StemRIM's last 12 months FCF is ($10M). |
| What is the current EV/FCF multiple of StemRIM? | Current FCF multiple of StemRIM is (7.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.